Lung Cancer

When first diagnosed with lung cancer, some doctors told Bonnie J. Addario that there was nothing that they could do for her. Now, 14 years later, she has spent over a decade helping others with the disease through her Bonnie J. Addario Lung Cancer Foundation.

A newly developed blood test may identify people at an increased risk for lung cancer, even if they are not within the screening guidelines.

"Scanxiety" is common in people with cancer, but is particularly prevalent in those with lung cancer, according to a recent survey.

Investigators at The University of Texas MD Anderson Cancer Center in Houston discovered that adding the PARP inhibitor veliparib to a standard chemotherapy regimen improved overall responses rates (ORR) in patients with relapsed small cell lung cancer (SCLC).

The majority of adolescent and young adult (AYA) patients who are diagnosed with cancer are expected to live past the five-year mark, though survival and health outcomes seem to differ by disease type, according to recent research published in the journal Cancer.

Five leading cancer organizations came together to establish four steps that patients of all malignancies can turn to as they navigate their experience.

As the field of lung cancer continues to evolve, here are some of the key discussions patients should have with their health care team, according to one expert.

Taylor Bell Duck was only 21 when she was diagnosed with lung cancer, a disease that is often stigmatized.

The partners will collaborate to empower the lung cancer community through educational efforts

The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.

According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.

A new expert guideline for managing immunotherapy’s side effects has been released.

Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

In the Keynote-042 trial, researchers found a four- to eight-month overall survival benefit among patients with non-small cell lung cancer (NSCLC), which was correlated with higher levels of PD-L1 expression, however, further study is warranted.

Some immunotherapy drugs target the PD-L1 protein, though this expert says that it is still an imperfect biomarker.

Racial disparities in palliative and hospice care beliefs appear to influence early integration in to standard oncologic care for patients with advanced lung cancer.

An expert from Texas Oncology offers perspective on findings from the CCGA study – presented at the 2018 ASCO Annual Meeting – which may support the use of a blood test to detect lung cancer earlier.